These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21046119)

  • 1. The genetic and clinical significance of MYCN gain as detected by FISH in neuroblastoma.
    Souzaki R; Tajiri T; Teshiba R; Higashi M; Kinoshita Y; Tanaka S; Taguchi T
    Pediatr Surg Int; 2011 Mar; 27(3):231-6. PubMed ID: 21046119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics.
    Jeison M; Ash S; Halevy-Berko G; Mardoukh J; Luria D; Avigad S; Feinberg-Gorenshtein G; Goshen Y; Hertzel G; Kapelushnik J; Ben Barak A; Attias D; Steinberg R; Stein J; Stark B; Yaniv I
    Am J Pathol; 2010 Jun; 176(6):2616-25. PubMed ID: 20395439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.
    Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S
    J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients.
    Wang M; Zhou C; Cai R; Li Y; Gong L
    Diagn Pathol; 2013 Jan; 8():5. PubMed ID: 23320395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of a slight increase in the gene dosage of MYCN in neuroblastoma determined using quantitative PCR.
    Souzaki R; Tajiri T; Higashi M; Kinoshita Y; Tanaka S; Kohashi K; Tsuneyoshi M; Taguchi T
    Pediatr Surg Int; 2008 Oct; 24(10):1095-100. PubMed ID: 18726105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.
    Berbegall AP; Villamón E; Piqueras M; Tadeo I; Djos A; Ambros PF; Martinsson T; Ambros IM; Cañete A; Castel V; Navarro S; Noguera R
    Oncogene; 2016 Mar; 35(11):1423-32. PubMed ID: 26119945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
    Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
    Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic significance of MYCN amplification in children neuroblastic tumors].
    Niu H; Xu T; Wang F; Chen Z; Gao Q; Yi P; Xia J
    Zhonghua Bing Li Xue Za Zhi; 2015 Feb; 44(2):111-7. PubMed ID: 25916642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
    Chen QR; Bilke S; Wei JS; Whiteford CC; Cenacchi N; Krasnoselsky AL; Greer BT; Son CG; Westermann F; Berthold F; Schwab M; Catchpoole D; Khan J
    BMC Genomics; 2004 Sep; 5():70. PubMed ID: 15380028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of unbalanced gain of distal chromosome 2p in neuroblastoma.
    Stallings RL; Carty P; McArdle L; Mullarkey M; McDermott M; O'Meara A; Ryan E; Catchpoole D; Breatnach F
    Cytogenet Genome Res; 2004; 106(1):49-54. PubMed ID: 15218241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification.
    Valent A; Le Roux G; Barrois M; Terrier-Lacombe MJ; Valteau-Couanet D; Léon B; Spengler B; Lenoir G; Bénard J; Bernheim A
    J Pathol; 2002 Dec; 198(4):495-501. PubMed ID: 12434419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Methods of detection and prognostic significance of genetic material increase of the short arm of chromosome 2 and a deletion of the short arm of chromosome 1 in patients with neuroblastoma].
    Druĭ AE; Tsaur GA; Shorikov EV; Popov AM; Plekhanova OM; Typonogov SN; Savel'ev LI; Tsvirenko SV; Fechina LG
    Vopr Onkol; 2013; 59(5):591-8. PubMed ID: 24260886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological diagnosis for neuroblastoma using the combination of highly sensitive analysis of prognostic factors.
    Tajiri T; Tanaka S; Higashi M; Kinoshita Y; Takahashi Y; Tatsuta K; Suita S
    J Pediatr Surg; 2006 Mar; 41(3):560-6. PubMed ID: 16516635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant DDX1 and MYCN gain in neuroblastoma.
    Defferrari R; Tonini GP; Conte M; Papio F; Sementa AR; Valent A; Schena F; Perri P; Mazzocco K
    Cancer Lett; 2007 Oct; 256(1):56-63. PubMed ID: 17611020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
    Hu HL; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma.
    Weber A; Imisch P; Bergmann E; Christiansen H
    J Clin Oncol; 2004 Jul; 22(13):2681-90. PubMed ID: 15226335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene.
    Carén H; Erichsen J; Olsson L; Enerbäck C; Sjöberg RM; Abrahamsson J; Kogner P; Martinsson T
    BMC Genomics; 2008 Jul; 9():353. PubMed ID: 18664255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of MYCN status in neuroblastoma by fluorescence in situ hybridization.
    Wan TS; Ma ES; Chan GC; Chan LC
    Int J Mol Med; 2004 Dec; 14(6):981-7. PubMed ID: 15547663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q.
    Boensch M; Oberthuer A; Fischer M; Skowron M; Oestreich J; Berthold F; Spitz R
    Diagn Mol Pathol; 2005 Sep; 14(3):177-82. PubMed ID: 16106200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYCN overexpression is associated with unbalanced copy number gain, altered nuclear location, and overexpression of chromosome arm 17q genes in neuroblastoma tumors and cell lines.
    Kuzyk A; Booth S; Righolt C; Mathur S; Gartner J; Mai S
    Genes Chromosomes Cancer; 2015 Oct; 54(10):616-28. PubMed ID: 26171843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.